Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools
Diffuse large B-cell lymphoma (DLBCL) has undergone a profound transformation in its therapeutic landscape over the past decade, driven by advances in molecular characterization and the emergence of targeted immunotherapies. Although standard immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine...